Renal Cell Carcinoma Drug Gains Approval Apr 16, 2012 The FDA has approved axitinib (Inlyta, Pfizer) for the treatment of advanced renal cell carcinoma (RCC). The drug is given twice daily and indicated for patients who have not responded to other RCC cancer medications. Source: FDA. Author Janine Anthes View all posts